Adverse drug reaction: Pomalidomide-induced liver injury

The Lancet

Volumn 383, Issue 9935, 2014, Pages 2125-2126

  Veluswamy, Rajwanth R ^a   Ward, Stephen C ^a   Yum, Kendra ^a   Abramovitz, Rebecca B ^a   Isola, Luis M ^a   Jagannath, Sundar ^a   Parekh, Samir ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; POMALIDOMIDE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PREDNISONE; RAPAMYCIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CASE REPORT; CYTOGENETICS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG POTENCY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; GENE DELETION; GENE TRANSLOCATION; HUMAN; HYPERTRANSAMINASEMIA; LETTER; LIVER INJURY; MAINTENANCE THERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PRIORITY JOURNAL; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT INJURY; CHIMERA; CHOLESTASIS; CHROMOSOME 11; CHROMOSOME 14; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HEPATITIS; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; LIVER FUNCTION; LOBULAR HEPATITIS; POMALIDOMIDE INDUCED LIVER INJURY; SALVAGE THERAPY; TOXIC HEPATITIS; TREATMENT RESPONSE; TUMOR RECURRENCE; URINE COLOR;

DRUG-INDUCED LIVER INJURY; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 84902667432     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61030-8     Document Type: Letter

References (6)

1. Hoffmann M, Kasserra C, Reyes J, et al. Absorption, metabolism and excretion of [14C] pomalidomide in humans following oral administration. Cancer Chemother Pharmacol 2013; 71: 489-501.
2. Teschke R, WolffA, Frenzel C, Schwarzenboeck A, Schulze J, EickhoffA. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol 2014; 6: 17-32.
3. Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood 2013; 122: 2799-806.
4. Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 1055-66.
5. Revlimid [package insert]. Summit: Celgene Corporation, 2013. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fa97bf5-28a2-48f1-8955- f56012d296be (accessed June 10, 2014).
6. Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. Hepatology 2000; 32: 1265-71.